

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gather and maintaining the data needed, and completing and reviewing the collection information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (OMB#0925-0753). Do not return the completed form to this address.

DTL Signed on 13-OCT-2023

| Protocol Information | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|--------------------------------------------------|
| CTEP Document Number A021502 | Phase III | Lead Protocol Organization ALLIANCE |
| Protocol Title Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair | | |
| Site Information | | |
| Research Site Name [REDACTED] | Site ID 76105 | Address [REDACTED] Bochum, 44791 DE |
| Clinical Investigator Information | | |
| Person ID [REDACTED] | Name of Clinical Investigator [REDACTED] | |
| IRB of Record | | |
| IRB # [REDACTED] | IRB Name [REDACTED] | Address [REDACTED] |
| Laboratory Information | | |
| No protocol specific labs required. | | |

Delegation of Tasks Log

| # | Ctep Person ID | Person | Research Task |
|------------------------------|----------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Clinical Investigator | | | |
| 1 | [REDACTED] | [REDACTED] | Consenting Person,Eligibility Assessment,End Point Assessment,Enrolling Person/Treating Investigator,HP Assessments,IND Prescribing,Investigational Product Accountability,OPEN Registrar,Tox Assessment |
| Sub-Investigators | | | |
| 1 | [REDACTED] | [REDACTED] | DTL Administrator,OPEN Registrar,Rave CRA |
| 2 | [REDACTED] | [REDACTED] | Consenting Person,DTL Administrator,Eligibility Assessment,End Point Assessment,Enrolling Person/Treating Investigator,HP Assessments,IND Prescribing,OPEN Registrar,Rave CRA,Tox Assessment |
| 3 | [REDACTED] | [REDACTED] | OPEN Registrar,Rave CRA |
| 4 | [REDACTED] | [REDACTED] | Consenting Person,Eligibility Assessment,End Point Assessment,Enrolling Person/Treating Investigator,HP Assessments,IND Prescribing,Tox Assessment |
| 5 | [REDACTED] | [REDACTED] | Consenting Person,Eligibility Assessment,End Point Assessment,Enrolling Person/Treating Investigator,HP Assessments,IND Prescribing,Tox Assessment |
| 6 | [REDACTED] | [REDACTED] | OPEN Registrar,Rave CRA |
| 7 | [REDACTED] | [REDACTED] | Consenting Person |
| 8 | [REDACTED] | [REDACTED] | Consenting Person,Eligibility Assessment,End Point Assessment,Enrolling Person/Treating Investigator,HP Assessments,IND Prescribing,Tox Assessment |

Commitments

I agree to conduct the protocol(s) in accordance with the relevant documents and will only make changes in a protocol after notifying the sponsor or responsible organization, except when necessary to protect the safety, rights, or welfare of subjects.

I agree to personally conduct or supervise the described investigation(s).

I agree to inform any patients, or any persons used as controls, that the agents/interventions are being used for investigational purposes (if applicable) and I will ensure that the requirements relating to obtaining informed consent and Independent Ethics Committee (IEC) review and approval in ICH E6, national and regional legislation, and the Declaration of Helsinki are met.

I agree to report to the sponsor or responsible organization any adverse experiences that occur in the course of the investigation(s) in accordance with ICH E6, national and regional legislation, and the Declaration of Helsinki. I have read and understand the information in the investigator's brochure (if an investigational agent is being used) or approved product labeling/marketing authorization literature, including the potential risks and side effects of the agent.


I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the protocol(s) are informed about their obligations in meeting the above commitments.

I agree to maintain adequate and accurate records and to make those records available for inspection in accordance with ICH E6, national and regional legislation, and the Declaration of Helsinki.

I will ensure that an IEC that complies with the requirements of ICH E6, national and regional legislation, and the Declaration of Helsinki will be responsible for the initial and continuing review and approval of the clinical investigation. I also agree to promptly report to the IEC all changes on the research activity and all unanticipated problems involving risks to human subjects or others. Additionally, I will not make any changes in the research without IEC approval, except where necessary to eliminate apparent immediate hazards to human subjects.

I agree to comply with all other requirements, regarding obligations of clinical investigators and all other pertinent requirements in ICH E6, national and regional legislation, and the Declaration of Helsinki.

Signature

| Signature | Date | Printed Name |
|------------------------------------------------------------------------------------|-------------|---------------------------------------------------------------------------------------|
|  | 13-OCT-2023 |  |

I have acknowledged and agree that my electronic signature is the legally binding equivalent to my handwritten signature. Whenever I execute an electronic signature, it has the same validity and meaning as my handwritten signature. I will not, at any time in the future, repudiate the meaning of my electronic signature or claim that my electronic signature is not legally binding.